AbbVie Reports Second-Quarter 2025 Financial Results
1. AbbVie reports Q2 adjusted EPS of $2.97, up 12.1%. 2. Immunology portfolio net revenues increase 9.5% to $7.631 billion. 3. Rinvoq and Skyrizi show substantial revenue growth at 41.8% and 62.2%. 4. Humira revenues decrease significantly by 58.1% due to competition. 5. ABBV raises 2025 adjusted EPS guidance from $11.67-$11.87 to $11.88-$12.08.